BRAF and colorectal carcinoma: To investigate key genes involved in oxaliplatin resistance in CRC, we conducted genome-wide CRISPR/Cas9 screens in two CRC lines (SW620 and RKO) with distinct molecular backgrounds (KRAS/TP53 mutant; BRAF mutant/TP53 WT, respectively).